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Tuberculosis (TB) is one of the deadly diseases in the present era caused by 
Mycobacterium tuberculosis. Principally, this bacterium attacks the lungs, however, 
MTB Has been observed affecting any part of the human body including the 
kidney, spine, and brain. Drug-resistant progression and other associated proper-
ties of MTB become a major hurdle in drug discovery to fight against tuberculosis. 
Moreover, some of the challenging situations such as the low range of chemi-
cal agents, the time-consuming process of drug development, the shortage of 
predictive animal models, and inadequate information of the physicochemical 
evidence required for effective bacterial penetration, are additional hindrances 
for the pharmaceutical scientist. In the current chapter, we focus on challenges 
encountered during drug discovery and need to be overcome as M. tuberculosis has 
a substantial barrier in its lipid-containing cell wall to inhibit the influx of drugs 
which is the initial requirement of the drug to show its therapeutic effect. There is 
also an immediate need for efficient vaccine development which may show its effect 
on adolescents and adults along with infants. Investigation on key bacterial targets 
has been troublesome, in light of the vulnerability around the microenvironments 
found in vivo and subsequently, the importance of exceptional metabolic pathways. 
The manuscript is prepared after the extensive literature survey to explore the vig-
orous approaches in novel drug designing and in proposing potent drug targets. The 
re-engineering and repositioning of prominent antitubercular drugs are required to 
attain viable control.
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1. Introduction
Tuberculosis (TB), one of the most common deadly disease is caused by a 
bacterium called Mycobacterium tuberculosis. Robert Koch in 1882, isolated the 
mammalian strain and proved that the Mycobacterium tuberculosis plays a causative 
role in Tuberculosis. As per the latest WHO report approximately one-fourth of 
the world’s population are infected with Mycobacterium tuberculosis (Mtb), whereas 
5–10% of the total will develop TB disease during their lifetime [1, 2]. The WHO 
estimated that in 2018, about 10 million people were affected due to TB worldwide 
and 1.5 million people suffering from the ailment, including 2,51,000 people who 
additionally had HIV [3, 4]. In the past, TB was a major reason for death around the 
globe [5, 6]. In industrialized nations, TB is getting slow due to vast development 
and improvements in drugs and new antibiotics [5, 7].
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TB may exist in two forms, active (dynamic) TB and Latent TB. Dynamic 
tuberculosis is a condition where MTB causes contamination; regularly, in the 
lungs, albeit numerous frameworks can be included. Dynamic TB is a multiorgan 
illness brought about by essential disease or as reactivation of inert tuberculosis. 
As need be, dynamic tuberculosis could be essential tuberculosis or reactivation 
tuberculosis.
Latent TB happens when an individual has the TB microscopic organisms inside 
their body, however, the microbes are available in tiny numbers. They are moni-
tored by the body’s safe framework and do not bring on any indications. Individuals 
with idle TB do not feel wiped out and are not irresistible. They cannot give the TB 
microscopic organisms to others. Moreover, they will generally have an ordinary 
chest x-ray and a negative sputum test. It is regularly just realized that somebody 
has latent TB since they have had a TB test, for example, the TB skin test. There 
are two kinds of test that can be utilized. These are the TB skin test (TST) and the 
fresher IGRA blood test. In nations where there is a significant degree of TB, (for 
example, the high weight TB nations) most individuals may have latent TB.
Fortunately, most of the TB patients have latent infection i.e., bacteria are pres-
ent in the body but is not causing active disease. Hence at any one time, there are 
about 10 million people across the world with active tuberculosis infection and that 
causes deaths in about 10% of them. So, approximately there are 1 million deaths 
per year due to tuberculosis [8, 9]. The Mycobacteria principally target the lungs, 
moreover, it has been observed that M. tuberculosis may also reach and affect other 
parts of the body, such as the kidney, spine, and brain. A few people get tuberculo-
sis ailment long after getting contaminated, even before their immune system can 
battle against the TB bacteria. Others may get the ailment years after the fact when 
their immune system gets frail for some other reason [8, 10].
Tuberculosis possesses a genuine risk to human wellbeing and one of the main 
reasons for significant human demise on the planet. Moreover, the emergence of 
drug resistance and its relationship with HIV infections have intensified worldwide 
circumstances. Unfortunately, despite advanced modalities for diagnosis and treat-
ment of TB, people are still suffering a lot. There are specific properties associated 
with MTB that has presented vast challenges to develop an efficient drug against 
Tuberculosis [11]. The major obstacles in TB treatment like screening of compounds 
with anti-tubercular activity, the long duration medication, the lack of predictive 
animal models, and insufficient information on the physico-synthetic properties 
required for successful bacterial penetration [12], are being encountered by the 
pharmaceutical scientist.
The danger of creating dynamic (active) Tuberculosis ascends to 30% in diabe-
tes victims. Usually, 80% - 90% of the patient having an infection of drug-resistant 
tuberculosis are relieved by taking concentrated anti-toxin treatment [2]. However, 
treatment by antibiotics is dependent on a load of drug-resistant M. tuberculosis 
in the patient [13]. Therapy of anti-drug or multidrug-resistant Tuberculosis 
(MDRTB: impervious to isoniazid and rifampin) is increasingly perplexing and 
takes nearly 2 years of chemotherapy amalgamation [14, 15]. Thus, progressively 
viable medicines are necessary to avoid or the emergence of tuberculosis. Treatment 
of the significant levels of drug-resistant Mycobacterium tuberculosis contamination, 
which incorporate rifampin-resistant (Rif-TB), MDR-TB, and extensively resistant 
TB (XDR-TB) requires new medications method and approaches to combat [5, 10]. 
The development of new methods of treatment is a complex process as anti-
tuberculosis drugs are mostly given in combination to inhibit the further emergence 
of drug-resistant TB [14]. Moreover, dormant TB has also been observed in many 
people in which TB is not in a dynamic position and do not show any symptoms 
in a patient [16] whereas dynamic TB happens when the body cannot possess the 
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TB pathogen but at this condition, the bacteria can reproduce and cause wanted 
symptoms and people with dynamic TB can spread the contamination [9, 15]. In 
certain condition, some MTB strains are not affected by the treatment method and 
hard to treat tuberculosis [17, 18].
2. Need of research on new TB vaccine
In recent decades, advanced diagnosis and treatment method of TB has reduced 
the mortality rate up to significant level but TB still exists in world population 
causing extensive human suffering, economic burden led to global inequity. There 
are neonatal BCG vaccines that can prevent infants and young children from severe 
forms of TB but this vaccine is unable to show its effect in adolescents and adults 
who are crucial in TB transmission. We need to develop new efficient vaccines 
which could work in all age group people that may assist to fulfill the WHO end TB 
strategy that aims to reduce the TB mortality and TB incidences by 95% and 90% 
respectively worldwide.
Now, WHO is putting much efforts to produce TB vaccines and the Product 
Development for Vaccines Advisory Committee (PDVAC) is asking to develop a 
WHO preferred Product Characteristics (PPC) for new TB vaccines. The WHO’s 
PPC data was established to document the crucial and priority requirements for vac-
cines which may show better safety and efficacy compared to BCG vaccine which is 
given to neonates and infants against pulmonary TB in adults, and new TB vaccines.
The major vaccine platforms like whole-cell vaccines, adjuvanted proteins, and 
recombinant subunit vector vaccines, are being considered in the pipeline of TB 
vaccine development. Now focus is on TB treatment in adolescents and adults by 
developing an effective candidate vaccine that may also replace the BCG in early life 
immunization. Many other aspects are in consideration in vaccine development, 
such as BCG boosters, reduction of treatment period using immunotherapeutic 
adjuncts and vaccine to prevent diseases reoccurrence in TB patient.
In recent developments, as per WHO report, there is TB vaccine candidate 
(M72/AS01E) developed by the pharmaceutical company GlaxoSmithKline, in part-
nership with AERAS and was observed substantially effective against Tuberculosis 
disease and these results came out in a Phase IIb trial carried out in Kenya, South 
Africa and Zambia in patients having latent tuberculosis. This vaccine was found 
with 50% efficacy over about 3 years of continuous monitoring.
3. Globally situation of tuberculosis
According to the report of WHO, a sum of 1.4 million individuals passed on from 
TB in 2019 (counting 208,000 individuals with HIV). Around the world, TB is one of 
the top 10 reasons for death and the main source from a solitary irresistible specialist 
(above HIV/AIDS). In 2019, an expected 10 million individuals became sick with 
tuberculosis (TB) around the world. 5.6 million men, 3.2 million ladies and 1.2 million 
youngsters. In 2019, 1.2 million kids became sick with TB worldwide. The youngster 
and juvenile TB is frequently ignored by wellbeing suppliers and can be hard to 
analyze and treat. In 2019, the 30 high TB trouble nations represented 87% of new 
TB cases. Eight nations represent 66% of the aggregate, with India driving the tally, 
trailed by Indonesia, China, the Philippines, Pakistan, Nigeria, Bangladesh and South 
Africa. Multidrug-safe TB (MDR-TB) stays a general wellbeing emergency and a well-
being security danger. A worldwide all out of 206 030 individuals with multidrug-or 
rifampicin-safe TB (MDR/RR-TB) were identified and told in 2019, a 10% expansion 
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from 186 883 out of 2018. Internationally, the TB rate is falling at about 2% each 
year and somewhere in the range of 2015 and 2019, the combined decrease was 9%. 
This was not exactly most of the way to the End TB Strategy achievement of a 20% 
decrease somewhere in the range of 2015 and 2020. An expected 60 million lives were 
saved through TB analysis and treatment somewhere in the range of 2000 and 2019. 
Finishing the TB plague by 2030 is among the wellbeing focuses of the United Nations 
Sustainable Development Goals (SDGs). Tuberculosis generally influences grown-ups 
in their most gainful years. Nonetheless, all age bunches are in danger. More than 95% 
of cases and passings are in non-industrial nations. Multidrug-resistant tuberculosis 
(MDR-TB) is a type of TB brought about by microbes that do not react to isoniazid 
and rifampicin, the 2 best first-line hostile to TB drugs. MDR-TB is treatable and 
reparable by utilizing second-line drugs. Nonetheless, second-line treatment choices 
are restricted and require broad chemotherapy (as long as 2 years of treatment) with 
meds that are costly and poisonous.
Sometimes, more serious medication opposition can create. TB brought about 
by microbes that do not react to the best second-line hostile to TB medications can 
leave patients with no further treatment alternatives.
In 2019, MDR-TB stays a general wellbeing emergency and a wellbeing security 
danger. A worldwide total of 206 030 individuals with multidrug-or rifampicin-safe 
TB (MDR/RR-TB) were identified and advised in 2019, a 10% increment from 186 
883 out of 2018. About portion of the worldwide weight of MDR-TB is in 3 nations – 
India, China and the Russian Federation.
Around the world, just 57% of MDR-TB patients are presently effectively 
treated. In 2020, WHO suggested another more limited (9–11 months) and com-
pletely oral routine for patients with MDB-TB. This exploration has shown that 
patients think that it’s simpler to finish the routine, contrasted and the more drawn-
out regimens that last as long as 20 months. Protection from fluoroquinolones ought 
to be rejected preceding the commencement of treatment with this routine.
As per WHO rules, the discovery of MDR/RR-TB requires the bacteriological 
affirmation of TB and testing for drug obstruction utilizing quick sub-atomic 
tests, culture strategies or sequencing advancements. Treatment requires a course 
of second-line drugs for at any rate 9 months and as long as 20 months, upheld 
by advising and checking for unfavorable occasions. WHO prescribes extended 
admittance to every single oral routine. Before the finish of 2019, 89 nations began 
utilizing more limited MDR-TB regimens and 109 had imported or begun utilizing 
bedaquiline, with an end goal to improve the viability of MDR-TB treatment.
4. The course of events in Mycobacterium tuberculosis
Mycobacterium tuberculosis basically passes through the 5 stages during its 
life cycle. At the first stage, the bacteria are inhaled through the air and typically 
engulfed by alveolar macrophages, further proceed to the symbiosis stage and caus-
ing the caseous necrosis in later stages. Eventually spread to other cells and causing 
rapid spread of diseases. The whole cycle is presented in detail in Figure 1 and as a 
flow chart in Figure 2. The Mycobacterium gets entry into the lungs and resides in 
the alveoli of the lungs while it begins its primary infection. If the immune system 
fails to eliminate it then there are three cases observed with the mycobacterium 
in the alveoli. The first case could be the elimination phase, in which the immune 
system completely eliminates the infection. The next one retention phase where the 
immune system suppresses the infection but the bacteria remain viable and, in this 
case, the infection is known as Latent Tuberculosis which is the most asymptomatic 
Tuberculosis. And the third phase may involve Active infection, which makes the 
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mycobacterium capable of evades the immune response and separates the infec-
tion in the lung tissue and at this point of active infection it is known as Active 
Tuberculosis [19–21].
M. tuberculosis has 5 stages in its life cycle as mentioned in Figure 2 as flow chart 
[1, 2, 7, 22].
Figure 1. 
Life cycle of Mycobacterium tuberculosis. This presentation is influenced with the figure available at 
online resource on study of the tuberculosis. (https://sites.google.com/site/mycobacteriumtbstudy/home/
life-cycle-of-organism).
Figure 2. 
Flow chart presentation of life cycle of Mycobacterium tuberculosis.
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5. Pathogenesis and transmission of Mycobacterium tuberculosis
If somebody has active lung disease with TB they will cough and, in the cough, 
there would be infected droplets carrying the bacteria that could be inhaled by 
somebody else [8, 15]. Once the bacteria is inhaled it goes into the lungs and then 
it invades the normal mechanism for protecting lungs against bacterial infec-
tion which are the alveolar macrophages. It actively seeks out and invades these 
macrophages because it can prevent the normal macrophage killing mechanism. 
So, it diverts the normal figure lysosome pathways and that allows it to survive 
in the macrophage and it can be latent in that macrophage for decades [3]. Also, 
Macrophages because they move will allow the bacterium to spread bull RAC across 
the body and this is one of the reasons why sites of immune functions such as the 
lymph nodes often get infected with Tuberculosis and long-term persistence within 
the macrophages is led to latent diseases [18]. Besides, there is a certain inflamma-
tory response to this infection which causes a very distinctive histologic appearance 
called granulomas and that is one of the hallmarks of Tuberculosis infection. Our 
closest infection is the presence of granulomas in the infected tissue [5, 6]. This 
transmission process is represented in Figure 3.
6. Mechanism of drug-resistant TB
This has been observed that various mechanism of drug resistance in M. tuber-
culosis is involved.
6.1 Presence of cell wall
The basic property leading to passive resistance to antibiotics in M. tuberculosis 
is because of its impervious cell wall [23]. The hydrophilic layer of arabinogalactan 
ensures the impervious nature of the cell wall to the surrounding hydrophobic 
substances. This layer is also present in hydrophobic mycolic acids which significantly 
Figure 3. 
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prevents the entry of hydrophilic molecules [24]. This impervious nature of the cell 
wall results in the deposition of antibiotics throughout the cell wall, the accumulated 
antibiotics near the cell wall are removed steadily by the release of enzyme & with the 
involvement of several cellular components [25]. It is demonstrated that β-lactams, 
which act as inhibitors to the inclusion of peptidoglycan (responsible for maintaining 
the rigidity of the cell wall) into the cell wall, are degraded by the mycobacteria due 
to the presence of β-lactamases, which are the enzyme responsible for degradation of 
β-lactam antibiotics. Danilchanka et al. [24], reported the presence of CpnT channel 
protein in the outer membrane of both M. tuberculosis and M. bovis, which plays a 
dual role in nutrient absorption and selective sensitivity to antibacterial agents.
6.2 Slow metabolism mechanism
Bacteria that have long-generation time & undergo metabolic processes with a 
slower rate are estimated to be challenging targets for most of the antibiotics i.e., 
bacteria that are metabolically active and rapidly replicating act as a good target 
for antibiotics [26]. However, in M. tuberculosis, it is still unclear whether the 
long generation time confirms its resistance to drugs. However, it is been reported 
that the slow growth rate of M. tuberculosis plays a crucial role in drug resistance. 
For example, antibiotics such as carbapenems lose their activity comparatively 
at a faster rate than the growth rate of M. tuberculosis [27]. It is seen that certain 
specific genes which are involved in the production of triacyl-glycerol permit the 
growth of M. tuberculosis even in oxygen-deprived conditions. Triacylglycerol 
decline in the metabolic processes of M. tuberculosis.
6.3 Possession of numerous efflux pumps
These protein channels play a vital role in the regulation of normal metabolism 
and the physiology of the organism such as toxins, signaling molecules through 
the cell wall, residues, and nutrient transport [28]. Efflux pumps have shown 
adaptation to drug resistance in M. tuberculosis. Multi-drug efflux pumps serve 
as an outlet for cell antibiotics and usually pass through both the inner and outer 
membranes of the cell [29]. Regulatory protein systems are present in Drug-efflux 
proteins which are responsible for controlling the expression of the efflux pump 
and thus helps in specializing them for drug resistance roles [28].
6.4 Mutation in genetic materials
It has been shown that the acquisition of antibiotics resistance in M. tuberculosis 
is the result of spontaneous mutation in several chromosomal genes. This frequent 
mutation has been found to cause a deliberate alteration to the required interaction 
between each drug against tuberculosis and its specified target.
M. tuberculosis shows resistance to rifampicin due to mutation in rpoB of RNA 
polymerase, decelerating its affinity for rifampicin [30]. It has been identified in 
certain studies that specific codons can cause resistance to rifampicin only with the 
onset of mutation in them [31, 32]. Resistance to pyrazinamide is due to mutation in 
the pncA gene [33, 34]. The mutations in pncA gene account for the large number 
of resistance cases reported in Mycobacterial tuberculosis.
The mode of action of isoniazid resistance is complex and remains unclear, 
however, most strains of Mtb resistant to isoniazid are associated with a mutation 
in KatG and inhA [35, 36]. S315T of KatG mutation is more common in isoniazid-
resistant strains. Mutation at this phase results in the formation of isoniazid product 
with a low affinity for isoniazid adduct [37].
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Mutations in embB497 and embB406, codon 306 in embB and Polymorphism 
in embA, embC, are all involved in ethambutol resistance [38]. In 2013, Safi et al. 
proposed that the mutation in ubiA (Rv3806c) showed a high level of ethambutol 
resistance [39]. Some investigators have reported that the mutations in tlyA gene 
play a vital role in the resistance of Viomycin and Capreomycin [40, 41].
7. Extrapulmonary tuberculosis (EPTB)
TB as a rule influences the lungs, however, it can likewise influence different 
pieces of the body, like the brain, the kidneys, or the spine. An individual with TB 
can pass on if they do not get treatment. TB influencing any piece of the body other 
than lung parenchyma including different structure inside the chest like the pleura, 
pericardium and perihilar lymph hubs, alluded as extra aspiratory tuberculosis. 
EPTB incorporates tuberculosis meningitis, stomach tuberculosis (for the most 
part with ascites), skeletal tuberculosis, Pott’s infection (spine), scrofula (lymph-
adenitis), and genitourinary (renal) tuberculosis. Scattered, or miliary tuberculosis 
regularly incorporates aspiratory and extrapulmonary locales. It is assessed that 
extrapulmonary tuberculosis (EPTB) represents 15–25% of all instances of TB. HIV 
patients, particularly with low CD4 tallies, have higher paces of EPTB. Youngsters 
are bound to have skeletal TB than grown-ups [42]. Approximately 10% of all TB 
cases have both pulmonary and extrapulmonary TB, and an additional 20% have 
EPTB without pulmonary involvement [2, 43].
8. Major limitations and considerations to work with M. Tuberculosis
Mycobacterium tuberculosis is a gradually developing bacteria which must be 
handled cautiously under exacting containment to minimize the hazard to research 
centre individual [4]. The bacterium can reproduce inside the macrophage and 
kill the immune cell. Another limitation presented by the bacteria in the innova-
tive work of new drugs is the idea of its cell wall which is wealthy in lipids and 
ultimately makes the development of homogenous and single-cell culture and 
troublesome [2]. M. tuberculosis can evade the immune response and recreate inside 
macrophages coming about because of several bacterial variables which along these 
lines can modulate the immune reaction [4, 5]. Although M. tuberculosis is Gram-
positive bacteria its cell wall resembles the external membrane of Gram-negative 
bacteria since it is composed of an asymmetric bi-layer containing particular 
mycolic acids, along with glyco-lipids, lipo-glycans, and proteins [3, 9]. Therefore, 
novel drugs with viability and quicker acting mechanism which can most likely 
work in the shorter-term and along these lines give better outcomes in the treat-
ment are desperately required [7].
9.  Possible opinion regarding the challenges of new drug discovery  
for tuberculosis
Besides, the development of XDR strains of M. tuberculosis, 5.4% of MDR-TB 
cases are discovered to be XDR-TB (World Health Organization, 2010, Ref. [3]). 
Multidrug and Extensive Drug-Resistant Tuberculosis: 2010 Global Report on 
Surveillance and Response (World Health Organization, 2010, Ref. [4]) is testing 
TB treatment programs in a few nations and even raises the chance of a re-visita-
tion of a circumstance much the same as the pre-anti-microbial TB time [1]. As 
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of now, MDR-TB is treated by a blend of eight to ten medications with treatments 
enduring up to 18 two years; just four of these medications were really evolved 
to treat TB5. Such imperfect treatment prompts practically 30% of MDR-TB 
patients to encounter treatment disappointment [44]. The treatment alternatives 
for XDR-TB are exceptionally restricted as XDR-TB bacilli are safe not exclusively 
to isoniazid and rifampicin, yet in addition to fluoroquinolones and injectables, 
for example, aminoglycosides. Furthermore, there are not kidding results with 
most MDR-TB and XDR-TB drugs, incorporating nephrotoxicity and ototoxicity 
with aminoglycosides, hepatotoxicity with ethionamide and dysglycaemia with 
gatifloxacin [45]. In this manner, the current circumstance requires the prompt 
distinguishing proof of new frameworks that can address arising opposition and 
furthermore requests the direct of suitable clinical preliminaries as verifiably 
not very many clinical examinations have been performed to assess the adequacy 
of medications in MDR-TB or XDR-TB patient gatherings. Improving the diag-
nostics with more extensive inclusion of medication vulnerability testing will 
likewise assist with tending to the high mortality of MDR/XDR-TB and control 
the development of obstruction.
Critical difficulties exist in TB drug revelation because of the idea of the 
causative bacterium. The absence of prescient models for compound section into 
mycobacteria is likewise a restricting variable since the direct trial proof is arduous 
to get. Creating essential guidelines around compound passage and efflux could 
help with improving hits from biochemical screens which need entire cell action, 
just as adjusting the synthetic properties needed for great pharmacokinetic  
properties [8].
10. Existing and upcoming tuberculosis drug regime
The present routine of medication for drug-sensitive Tuberculosis treatment 
was set up during the 1980s. This treatment process encompasses four levels of 
medications, isonicotinic acid hydrazide, rifampin, Ethambutol dihydrochloride 
and Pyrazinoic acid amide for six months of treatment (Table 1). The essential 
focus of Tuberculosis drugs is cell wall biogenesis, deoxyribonucleotide replication, 
ribonucleotide transcription, and protein synthesis [15, 46].
Treatment of drug-resistant or multidrug-resistant (MDR) tuberculosis is 
substantially further unpredictable [8]. The success of the treatment process relies 
upon the patient record and drug affectability. MDR-Tuberculosis needs therapy 
for a long time with a combination of 5 other medications. These second-line 
drugs will in general be progressively costly and incorporate Sirturo, 2-ethylthio-
isonicotinamide, Seromycin, Moxifloxacino, and Streptomycine, just like cutting 
edge medications rifampin systemic and Myambutol [5, 46]. For MDR tuberculosis 
therapy, we need to go through at least 6 months long treatment process including 
various vaccinations. Some have been observed to show adverse effects like heart 
electrophysiology dysfunction and ototoxicity [10, 13].
11. Drug combination trials and standardization of TB regimens
The WHO-recommended formulations of anti-TB drugs and fixed-dose com-
binations (FDCs) of drugs appear in the WHO Model List of Essential Medicines 
(available at www.who.int/medicines/publications/essentialmedicines/en). The 
formulations and combinations of anti-TB drugs available in each country should 
conform to this list.
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Normalized treatment implies that all patients in a characterized bunch get a 
similar treatment routine. Standard regimens have the accompanying benefits over 
the individualized solution of medications:
i. errors in remedy – and in this way the danger of advancement of medication 
opposition – are decreased;
ii. estimating drug needs, buying, circulation and checking are encouraged;
iii. staff preparing is encouraged;
iv. costs are decreased;
v. maintaining a regular drug supply when patients move to start with one 
region then onto the next is made simpler;
vi. outcome assessment is helpful and results are tantamount.
12.  Pharmaco-kinetic and pharmaco-dynamic contemplations  
for tuberculosis medications
Pharmacokinetic (PK) and pharmacodynamics (PD) properties of a medicinal 
drug play a substantial role to propose its feasibility for medicinal purpose In vivo 
[47, 48]. Along with the PK/PD of any anti-tubercular drugs, medication also 
considers other factors like comorbid conditions, safety profile, oral bioavail-
ability and metabolic strength [4, 10]. Oral administration is mostly preferred for 
advanced Tuberculosis medication whereas, oral bioavailability is critical to treat 
Tuberculosis [4, 46]. Solubility and gastrointestinal permeability are the two major 
factors that affect oral bioavailability. At present. Generally, the bioavailability of 
tablets Tuberculosis ranges from 40–90% and new drugs must show such property 
of bioavailability [2, 7]. The smaller successive dosing of drugs is suggested to 
improve the adhesion and recommend to have daily doses. An ideal TB medicine 
must transmit to the lungs, the site of the primary infection, and should have the 
Drug Drug property Acting pH Site of action
Isoniazid (H) Bactericidal after 24 hrs with a high 
potency.
Kills more than 90% of bacilli in first 




Both intracellular and 
extracellular









Bactericidal with a low potency Acidic medium Intracellular bacilli
Ethambutol (E) Bacteriostatic with a low potency. 













Current drugs and their property.
11
Challenges in Drug Discovery against Tuberculosis
DOI: http://dx.doi.org/10.5772/intechopen.97857
ability to infiltrate the granuloma to reach, such as intracellular and extracellular 
bacilli in the centre of hypoxia and undoubtedly necrotic region [9]. Preferably, the 
adhesion of drugs compounds in the target tissue must be maintained at a chosen 
site at minimal inhibitory conditions [49, 50]. This approach is used to avoid the 
phenomenon of drug binding to plasma protein, inhibition of tissue diffusion and 
improving the half-life of medicine. Lipophilic drugs have a major portion in anti-
tubercular drugs. PK/PD and mode of action determines the dose of drugs for the 
treatment [5, 6].
In terms of drug safety, an ideal drug for Tuberculosis should not show any acute 
toxicity or long duration for the treatment [47, 51]. Because of the global nature of 
Tuberculosis therapy, an excellent drug must not show drug–drug interaction with 
other chemically or biologically active TB drugs within the regime [7, 22].
13. Target identification
With the entire genomic sequence available for Mycobacterium tuberculosis, the 
potentiality to explore new targets for the development of antibiotic throughout 
the M. tuberculosis genome became convenient [9, 10]. Novel chemical entities & 
targets are expected to avoid resistance to existing drugs and therefore improve cur-
rent treatments. An ideal target for the development of antibiotic must necessarily 
be in vivo, vulnerable to medicines and drug-effective [6].
Genetic screens trials are the preliminary step in manifesting which genetic 
products might be targeted at chemotherapy against tuberculosis. Howsoever, all 
the necessary genes are not equally vulnerable to pharmacological action [20]. 
Besides, the target should also be available for competitive or chemical inhibition. 
That is, the target must have the ability to bind with another molecule rather than 
its substrate [10, 52, 53]. The inhibition or initiation of the protein function with a 
possible concentration of the low molecular weight compounds results in cellular 
breakdowns, such as cell death leading to apoptosis or attenuated growth [14, 46]. 
Besides being susceptible to chemical inhibition, an anti-target screen inhibitor 
should also produce drug-like compounds with specificity to affect target function 
in the absence of interference with any host orthologs [5, 54].
14. Current status of tuberculosis drug discovery
Various strategies have been developed by researchers and investigators and 
they proposed combined drugs for clinical trials after screening. All these drugs 
have a specific mode of actions but at the same time, they also showed some side 
effect which is a challenging task for investigators (Table 2). Currently, about 7 
new combinations of drugs are under clinical trials. These lead combinations have 
been recognized by several methods and differential screening [10]. Few screening 
methodologies are as follows:
14.1 SQ109
A combinatorial library entirely based on 1,2-ethylenediamines such as 
Ethambutol was examined on two high-throughput in-vitro analysis. The first 
evaluation involves dilution of bouillon to calculate minimal inhibitory concentra-
tion (MIC) contrary to Mycobacterium tuberculosis [55]. The subsequent measure-
ment is based on iniBAC promoter, inhibition of cell wall and bioluminescent assays 
for high-throughput screening [56]. SQ109 was determined on this screen. But the 
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mode of action and efficacy of SQ109 differ widely from ethambutol [57, 58]. SQ109 
is bactericidal in nature and works by targeting a transmembrane transport protein 
MmpL3 which is responsible for transmitting trehalose monomicolate during cell 
wall synthesis [59, 60]. It acts against extracellular as well as intracellular bacilli and 
works on acute and chronic mouse models of tuberculosis infection [61]. SQ109 
improved the pharmacological efficacy of the present four available first-line drugs 
against tuberculosis and represents synergy with Sirturo. It is presently under phase 
2 clinical studies [5, 15].
14.2 Q203
It is an amide compound of imidazopyridine and was recognized by the whole-cell 
screening of infected macrophages [17]. Q203 prevents ATP synthesis via causing an 
Mode of therapy Implemented 
Drugs
Possible adverse effects
First line oral agents
(Ref. 33, 34)
Isoniazid Hepatotoxicity, dermatological, gastrointestinal, 
hypersensitivity
Rifampicin Heartburn, epigastric distress, Thrombocytopenia, 
Leukopenia, hemolytic anemia, Menstrual disturbances 
etc.
Ethambutol Retrobulbar neuritis, gastrointestinal disturbance.
Pyrazinamide GI disturbances, Thrombocytopenia, sideroblastic 
anemia, Mild arthralgia myalgia etc.
Injectable anti-TB 
drugs
Streptomycin burning, crawling, itching, numbness, prickling etc.
Kanamicin pain or irritation
Amikacin diarrhea, hearing loss, spinning sensation (vertigo), 
numbness etc.
Fluroquinol drugs Ofloxacin Nausea, diarrhea, constipation, gas, vomiting etc.
Levofloxacin low blood sugar, headache, hunger, sweating, irritability 
etc.
Gatifloxacin red, irritated, itchy, or teary eyes, blurred vision, eye pain 
etc.
Second line oral 
drugs
Ethionamide Nausea, vomiting, diarrhea, abdominal/stomach pain etc.
Prothionamide depression and hallucinations
Cycloserine Headache, drowsiness, dizziness, or shaking etc.
p-Aminosalicylic 
acid
persistent nausea, vomiting and diarrhea etc.
Anti-TB drugs with 
long term safety
Linezolid severe diarrhea or diarrhea that is watery or bloody, 
fungal infections, low platelet counts etc.
Redaquiline Nausea / Vomiting, Dizziness, Headache, Hemoptysis etc.
Clofazimine diarrhea, nausea, vomiting, gastrointestinal intolerance 
etc.
Amoxicillin severe skin rash, itching, hives, difficulty breathing or 
swallowing etc.
High dose Isoniazid increased blood levels of liver enzymes and numbness 
etc.
Table 2. 
Current mode of therapy and therapeutic drugs for tuberculosis.
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interruption in the electron transport chain and thus also inhibits the cytochrome bc1 
complex involved in the electron transport mechanism. Q203 possess an exceptional 
Pharmacokinetic profile and prevents bacterial replication [2, 20].
14.3 TBA-7371
A member of a series of 1,4-azaindole which was recognized by a strategy of 
transformation of scaffolds preceded by a program of optimization of lead of a com-
pound imidazopyridine [62]. TBA-7371 inhibits DprE1 non-covalently, a decaprenyl 
phosphoryl-β-Dribose2′-epimerase, in cell wall Arabian biosynthetic pathway. TBA-
7371 is bactericidal and is working against both acute and chronic mouse models of 
tuberculosis infection. It is under phase 1 clinical studies [3, 46, 57].
14.4 OPC-167832
It is a derivative of 3,4-dihydrocarostyril. OPC-167832 is bactericidal and works 
by targeting DprE1, leading to the prevention of mycobacterial infection. It repre-
sents improved performance when in combination with delamide. Presently it falls 
under the category of phase 1 clinical studies [10, 15].
14.5 GSK-070
It targets leucyl-tRNA synthetase and is an oxaborole derivative. Oxaborols 
block leucyl-t-RNA synthesis and ultimately results in blocking protein synthesis 
by constructing an adduct with t-RNA. It is active against both acute and chronic 
tuberculosis infection [10, 63].
14.6 PBTZ-169 & BTZ-043
They belong to benzothiazinones and were diagnosed from a broth dilution 
evaluation in vitro for the detection of antibacterial and antifungal activities. 
Benzothiazinones basically prevents the formation of arabinose involved in the bio-
synthesis of cell wall by covalently targeting DprE1. Both PBTZ-169 and BTZ-043 
are bactericidal thus prevents bacterial replication and multidrug-resistant tubercu-
losis infection. They represent almost equal potency against isoniazid and rifampin 
in the mouse models of recurrent tuberculosis infection. PBTZ-169 is under phase 1 
scientific studies [7, 9, 63].
15. Risk factors associated with tuberculosis treatments
Recent emigration makes Tuberculosis very likely to reactivate. Vitamin D 
deficiency has the same effect because vitamin D is an immune modulator and 
deficiency of that weakens the immune system, thus protecting against tubercu-
losis [3, 9]. Another factor, HIV infection, which is present in 8% of patient cases 
of tuberculosis and this problem of HIV allowing TB to be reactive and become 
a problem is actually before the patient has become heavily immune-suppressed 
[64]. Smoking, diabetes and the elderly are all examples where the immune system 
has been weakened to a degree and allows the potential infection to take hold and 
cause a problem [22, 63]. Homelessness drug abuse, alcoholism and other immune 
suppression steroids after transplantation to mention corrosive tumor necrosis 
factor treatment, all make an individual more likely to reactivate latent disease, like 
tuberculosis [6]. The antibiotics being used for the TB treatment have also shown 
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some of the side effects and the present major challenge to researchers to overcome 
these drawbacks of antibiotics (Table 2).
16. Recent developments in diagnostic approaches for tuberculosis
It is not easy to conduct a clinal diagnosis of tuberculosis very frequently as 
confirmed diagnosis requires culturing the bacteria M. tuberculosis in a sample from 
the patient [5] and which is very slow-growing. For lung diseases, we take morning 
sputum for culture purpose and microscopic studies. We also have to do Biopsies 
of the affected tissues, because that will provide us with a sample for culture and 
also for looking histologically for the characteristic presence of granulomas [53]. 
Mycobacterial culture confirms the presence of mycobacterium in given samples 
by microscopy analysis, and we may also draw the resistance profile i.e., whether 
the present strain belongs to the sensitive M. tuberculosis group or has resistance to 
some drugs that can be used to treat it. The major obstacles in culture MTB are that 
it is slow-growing bacteria and may take 3–4 weeks in liquid culture media [51]. The 
acid-fast bacilli of mycobacterial infection are detected by the microscopy analysis 
whereas latent tuberculosis disease is identified by immunological responses to 
tuberculosis antigens, i.e., i) Heaf test / Montoux: cofounded by BCG ii) Interferon 
Gamma Release Assays (IGRA) [48, 49]. There are some tools developed recently 
for the detection of drug-resistant MTB that facilitates early detection too, such 
GeneXpert, line prob. assay, LAMP assay etc.
16.1 GeneXpert
GeneXpert can detect mutations that cause resistance against Rifampicin. The 
test is a molecular TB test that detects the DNA of Mycobacterium tuberculosis. It uses 
a sputum sample and thus provides result in less than 2 hours. It can also detect the 
genetic mutations which are associated with drug Rifampicin resistance [65]. WHO 
recommended that this test should be used as the primitive diagnosis test in indi-
viduals suspected of having Multi-drug resistant TB, or HIV associated TB.
16.2 Line probe assay (LPA)
This technique also helps to detects mutations causing resistance against 
Rifampicin. Moreover, this assay can also detect mutations related to drug isoniazid 
[66]. The line probe assay (LPA), is typically based on strip technology and thus is 
used in the diagnosis of TB. It also detects RIF as well as Isoniazid (INH) resistance 
caused due to mutations in rpoβ, and both inhA and katG genes.
16.3 Loop-mediated isothermal amplification (LAMP) assay
WHO has recommended the TB-LAMP (loop-mediated isothermal amplifica-
tion) test that requires minimal laboratory infrastructure and has been evaluated 
as an alternative to sputum smear microscopy, which remains the most widespread 
test used in resource-limited environments. TB-LAMP is a unique temperature-
independent way to amplify the DNA of tuberculosis patients. It is a manual test 
that takes less than one hour and results can be visualized with the naked eye under 
UV light. The potent TB-LAMP instrument can be used at the level of the peripheral 
health center where microscopy is often performed. (https://www.who.int/tb/
features_archive/TB_LAMP/en/).
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17. Available treatment
At present treatment of tuberculosis requires more than one antibiotic with pro-
longed combination therapies to eradicate the infection and prevent resistance [58] 
and the standard therapy may include 4 antibiotics i.e., Isoniazid & Rifampicin (most 
effective drugs and these are given for six months and thus these two helps in killing 
the bacteria), Pyrazinamide & Ethambutol (given for first two months only) [67, 68]. 
During treatment antibiotics are required for a long period, the minimum treatment 
period is six months and if the patient is having CNS or bone disease it often goes on 
for at least 12 months [69]. The patient is asked to take four drugs for two months and 
then followed by two drugs for four months, and the actual dose given to the patient is 
decided by their body weight such as if a patient is lower than 50 kg, they get a lower 
dose while if the patient is above 50 kg, they get a higher dose [13].
Corticosteroids are given to patients with CNS or pericardial disease because this 
reduces the further chances of having long term brain damage. All the cases need to 
be monitored and notified so that there can be a screening process of the patient’s 
close contacts as well [14, 17].
18. Conclusion
M. tuberculosis is a difficult pathogen to combat and the frontline drugs cur-
rently in use are between 40 and 60 years of age. There is an urgent need of novel 
tuberculosis drugs, but the time to identify, develop and ultimately advance new 
drug regimens on the market has been extremely slow in the past decade. Organic 
biochemistry remains to be performed to know the mechanism of activity, to 
empower lead advancement, and to ensure in vivo effectiveness [20]. Current efforts 
to develop drugs against tuberculosis are not enough to end the global tuberculosis 
epidemic. Due to the diversification and complexity of the infection for M tuberculo-
sis, no model can completely define the in-vivo conditions in which mycobacteria are 
found in Tuberculosis patients and there is no sole standard detection condition for 
generating successful compounds for tuberculosis drug development. Recent efforts 
have focused on the development of whole-cell screening trials because objective-
based biochemical screens of inhibitors over the past two decades have not provided 
new tuberculosis drugs [68]. There are significant challenges in the discovery of anti-
tuberculosis drugs due to the nature of the causative bacteria. The lack of predic-
tive models for the entry of compounds into mycobacteria is also a limiting factor. 
Several additional barriers in the development of tuberculosis drugs include: there 
are no well-established (PK)– (PD) paradigms, lack of validation and human-like 
pathology of animal models currently available for drug discovery, lack of clinical 
laboratories suitable for clinical trials, and the lack of adequate research funds. 
The biggest challenge in the development of anti-tuberculosis drugs is to reduce 
the duration of treatment for patients with drug-sensitive tuberculosis [18]. Noval 
drugs are needed to achieve this and overcome drug resistance. In addition, it should 
be possible to use new drugs for patients with HIV/AIDS co-infection. The present 
condition of tuberculosis drug development is far better than what was seen past 
10–15 years ago. Howsoever, the development is still lacking behind because of the 
significant challenges in the drug discovery against drug-resistant tuberculosis and 
the shorter duration of the treatment required for tuberculosis prevention [12, 13].
We need to identify essential Tuberculosis targets based on better knowledge of 
the disease pathogen and physiology, develop sharp screening trials, and prepare 
compounds specifically designed to provide better clues for antibacterial activities [11]. 
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Recent granuloma models are based on a single cell type to imitate the aggregate 
complex that is formed. Biomedical engineering methods can produce further 
diversified but still organized multicellular structures that clearly defines the 
organization of human granulomas. The challenge is that the need is urgent, but the 
process of discovery and development requires an excessive number of resources 
and time. The search for more effective vaccines should continue to provide long-
term solutions to tuberculosis. At the same time, the development of drugs and 
regimes must be accelerated with a clearer approach [1, 9].
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